DeCure's autonomous Metabolic AI scientist is researching a drug-repurposing hypothesis for thyroiditis — screening already-approved drugs against its 34-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleThyroiditis maps to a 34-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for thyroiditis is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
protein kinase cAMP-dependent type I regulatory subunit alpha (PRKAR1A) — PRKAR1A is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet pcgdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5KJZ · 1.347 Å · ligand CYCLIC GUANOSINE MONOPHOSPHATE (PCG). Experimental structure, not a prediction.
What the evidence adds up to
A 2006 review of autoimmune thyroiditis (Graves’ disease and Hashimoto’s thyroiditis) summarises genetic and environmental findings from studies published since January 2005. Susceptibility genes under investigation include CD40 and protein tyrosine phosphatase-22, in addition to the established major histocompatibility complex class II genes and cytotoxic T cell antigen-4. Excess iodine is reported to increase the incidence of Hashimoto’s thyroiditis, possibly by raising the antigenicity of thyroglobulin. The review also notes that T regulatory cells, Toll-like receptors, and CD1-mediated lipid antigen presentation are new areas of basic immunological investigation applied to autoimmune thyroiditis. No clinical trial data or treatment outcomes are reported.
A 2000 review describes the use of pathogenic thyroglobulin peptides as model antigens to study the induction and immunoregulation of autoimmune thyroiditis. It covers genetic control of immune responses to defined thyroglobulin epitopes, diversity of the T-cell receptor repertoire, and the role of hormonogenic sites (thyroxine residues) in generating thyroiditogenic cells. The review also discusses the search for microbial peptides that may act as molecular mimics in disease pathogenesis. No human treatment data are presented.
A 1970 report from Sweden describes 207 cases of thyroiditis observed between 1960 and 1968. Among 178 patients with chronic thyroiditis, 47 were operated on primarily, 130 received thyroid hormone, and one was untreated. Eleven patients later required surgery because of unsatisfactory response to hormone treatment. Subacute thyroiditis occurred in 29 cases, and focal thyroiditis with other thyroid diseases in 20 cases. All patients were followed continuously, but no response rates, survival data, or controlled comparisons are given.
A 1975 study of 31 patients with de Quervain’s thyroiditis (biopsy-confirmed in 15) found that seven had an acute course. The authors argue that the term “subacute” is misleading. Extremely rapid erythrocyte sedimentation rate with a normal peripheral leucocyte count was typical. The disease generally resolved completely within weeks to months; transition to immunothyroiditis or hypothyroidism was rare. Conventional antiinflammatory drugs combined with thyroid hormone gave a good therapeutic response. Corticosteroids were recommended only in exceptional cases. No randomised comparisons or long-term follow-up beyond general recovery are reported.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Current Opinion in Rheumatology · 2006 · 150 citations
Autoimmune thyroid diseases
AbstractPURPOSE OF REVIEW: Interesting clinical and basic studies have been published in the field of autoimmune thyroiditis (represented by Graves' disease and Hashimoto's thyroiditis) since January 2005. The review is organized into four main areas: genetics, environment, adaptive immune system, and innate immune system. RECENT FINDINGS: The quest continues for the identification of susceptibility genes for autoimmune thyroiditis. In addition to the classical major histocompatibility complex class II genes and cytotoxic T cell antigen-4, new studies have appeared on CD40 the protein tyrosine phosphatase-22. Too much iodine increases the incidence of Hashimoto's thyroiditis, perhaps by augmenting the antigenicity of thyroglobulin. T regulatory cells, Toll-like receptors and presentation of lipid antigens by CD1 molecules are new areas of basic immunological investigation that have been applied to autoimmune thyroiditis. SUMMARY: Overall, the studies have greatly expanded our understanding of the pathogenesis of thyroiditis. They have opened new lines of investigations that will ultimately result in a better clinical practice.
International Reviews of Immunology · 2000 · 19 citations
Pathogenic Thyroglobulin Peptides as Model Antigens: Insights on the Induction and Maintenance of Autoimmune Thyroiditis
AbstractIn recent years, the discovery of pathogenic thyroglobulin (Tg) peptides has given a new impetus to study, at the basic level, mechanisms of induction and immunoregulation of autoimmune thyroiditis. The genetic control of the immune response against defined Tg epitopes and the diversity of the T-cell receptor repertoire recruited for their recognition were among the first issues examined. Some of these epitopes contained hormonogenic sites, i.e. thyroxine residues, and thus offered an excellent opportunity to study how post-translational modifications such as iodination, can influence induction of thyroiditogenic cells. The delineation of pathogenic Tg determinants also enabled the search for "molecular mimics" i.e. peptides of microbial origin that may be involved in the pathogenesis of the disease. In addition, factors promoting the generation of pathogenic epitopes during Tg processing in antigen presenting cells could now be systematically investigated. This review summarizes recent findings in these areas.
AbstractAbstract. During the period 1960–1968 207 cases of thyroiditis were observed in the Second Department of Surgery of Sahlgrenska sjukhuset. All patients were continuously followed up. Subacute thyroiditis was seen in 29 cases, and focal thyroiditis together with other thyroid diseases in 20 cases. Of 178 patients with chronic thyroiditis, 47 were primarily operated upon, 130 patients were treated with thyroid hormone, and one patient was not treated. Eleven patients were operated upon later because of unsatisfactory response to the hormone treatment. This paper presents an account of the results of treatment. The principles of treatment of chronic thyroiditis are discussed.
DMW - Deutsche Medizinische Wochenschrift · 1975 · 6 citations
Zur Thyreoiditis de Quervain
AbstractAmong 31 patients with de Quervain's thyroiditis (confirmed by biopsy in 15) there were seven who had an acute course. It is, therefore, suggested that the misleading term "subacute" thyroiditis for this form of inflammatory thyroid disease be avoided. It is nowadays the most frequent form of painful thyroiditis seen in clinical practice. Extremely rapid ESR with normal peripheral leucocyte count is a typical finding. Generally the disease is completely cured within a few weeks to months, transition to an immunothyroiditis or hypothyroidism being rare. Conventional antiinflammatory drugs, combined with thyroid hormone, give a good therapeutic response. Corticoids should be used only in exceptional instances.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
